When is ICSI recommended? Intracytoplasmic sperm injection is most clearly indicated when there is a significant sperm-related problem, when sperm have been retrieved surgically, or when previous conventional IVF resulted in failed or very low fertilization. Current 2026 guidance does not support automatically adding ICSI to every IVF cycle simply because it is a more technically advanced procedure.
ICSI may help overcome a problem with sperm reaching or entering an egg. It cannot correct poor egg quality, guarantee normal embryo development, fix implantation problems or guarantee pregnancy.
Understanding this distinction can help couples discuss whether IVF with ICSI is medically justified in their particular situation.
ICSI, or intracytoplasmic sperm injection, is an IVF laboratory technique in which an embryologist injects one selected sperm directly into a mature egg.
In conventional IVF, prepared sperm and eggs are placed together in the laboratory and fertilization is allowed to occur without directly injecting a sperm into the egg.
With ICSI, the embryologist bypasses several of the steps a sperm would normally have to complete before entering the egg.
HFEA describes the remainder of the treatment pathway as largely the same as IVF; the important difference is how fertilization is attempted in the laboratory.
Slavica IVF provides ICSI treatment in Kathmandu as part of its assisted-reproduction services.
ICSI is not an alternative to IVF in the way that IUI is an alternative fertility treatment. ICSI is usually a fertilization technique used within an IVF cycle.
The earlier stages may include:
The difference occurs when mature eggs are fertilized.
Prepared sperm are placed with the eggs and fertilization is allowed to occur.
An embryologist selects a sperm and injects it directly into a mature egg.
After fertilization, embryos may then be cultured, assessed, frozen or transferred according to the treatment plan.
For readers comparing the overall fertility pathways, Slavica’s guide to IVF treatment in Kathmandu explains the wider IVF process.
Current guidance supports ICSI most strongly when there is a recognized reason to believe sperm may have difficulty achieving fertilization with conventional insemination.
NICE updated its fertility quality standard in March 2026. It states that ICSI should be offered when surgically retrieved sperm or frozen-thawed oocytes are being used, semen parameters are abnormal, or previous IVF produced failed fertilization or a very low fertilization rate.
HFEA similarly lists very low sperm count, poor sperm motility or morphology, previous poor fertilization and surgically retrieved sperm among situations in which ICSI may be recommended.
The clinical details still matter.
ICSI was originally developed largely to overcome severe male-factor fertility problems.
Possible sperm-related reasons include:
These findings usually come from a semen analysis assessing sperm concentration, motility, morphology and other semen characteristics. Slavica IVF lists semen analysis as part of its male fertility assessment pathway.
Importantly, a semen report should be interpreted as a whole.
A single number should not automatically determine whether someone needs ICSI.
When very few usable sperm are available, conventional IVF may provide fewer opportunities for successful sperm–egg interaction.
ICSI allows the embryology laboratory to use an individual viable sperm for a mature egg.
This is one of the most established uses of the technique.
However, “low count” covers a wide spectrum. Mild reductions are different from severe oligozoospermia, and the decision should consider count together with motility, morphology, sample preparation and previous reproductive history.
Markedly reduced sperm motility can be a reason to consider ICSI because sperm with poor movement may have difficulty reaching and penetrating the egg under conventional IVF conditions.
HFEA specifically includes abnormal movement among recognized situations in which ICSI may be recommended.
But the significance depends on how reduced the motility is, how many motile sperm remain after laboratory preparation and whether other semen parameters are also abnormal.
This is why patients should avoid interpreting the word “low” on a laboratory report as an automatic instruction to undergo ICSI.
Not necessarily.
Sperm morphology describes the proportion of sperm meeting defined structural criteria.
Severe abnormalities together with other sperm problems may contribute to an ICSI recommendation.
However, the 2026 ASRM committee opinion discusses a large randomized study in which men had abnormal morphology but otherwise normal count and motility. ICSI did not produce a statistically significant improvement in live birth compared with conventional IVF.
The practical message is:
Isolated abnormal morphology should not automatically be interpreted as proof that ICSI is better.
The entire male fertility picture matters.
Slavica also has a dedicated male fertility assessment guide covering male reproductive evaluation and fertility treatment.
ICSI is commonly used when usable sperm must first be retrieved directly from the epididymis or testicle.
Azoospermia means sperm are absent from the ejaculate. Depending on the cause, sperm may sometimes still be obtainable through procedures such as:
Slavica IVF lists TESA, PESA and TESE among its male surgical sperm-retrieval services.
HFEA specifically identifies surgically retrieved sperm as a recognized reason for ICSI.
Because the number, maturity and characteristics of surgically retrieved sperm may differ substantially from an ejaculated sample, direct injection can be particularly useful.
Severe male-factor infertility may also raise questions about an underlying genetic cause. Whether genetic testing or counselling is appropriate depends on the diagnosis and should be discussed individually.
Yes, previous total fertilization failure or unexpectedly low fertilization with conventional IVF is one of the strongest non-male-factor reasons to consider ICSI in a subsequent cycle.
Both NICE and HFEA identify previous failed or very poor fertilization as an indication.
ASRM’s 2026 committee opinion also concludes that ICSI can improve fertilization rates after lower-than-expected or failed fertilisation with conventional insemination.
This does not mean every failed IVF cycle should automatically be converted into an ICSI cycle.
The clinic should first determine where the previous treatment failed.
For example:
These are very different situations.
If fertilisation was normal and the problem occurred during later embryo development or implantation, ICSI may not address the main problem.
For a broader review of unsuccessful cycles, see Slavica’s article on what to consider when IVF attempts keep failing.
Yes, ICSI is commonly considered when previously frozen and thawed oocytes are fertilized.
NICE’s 2026 quality standard specifically includes frozen-thawed oocytes as an indication for ICSI.
ASRM’s 2026 guidance also identifies previously cryopreserved oocytes as a selected non-male-factor situation in which ICSI may offer benefit.
The exact approach should still be discussed with the embryology team because laboratory protocols and individual circumstances differ.
This requires a more precise answer than simply saying “PGT requires ICSI.”
HFEA notes that ICSI may be recommended for some genetic-testing situations where sperm adhering to the outside of the egg could interfere with testing.
However, not every form of preimplantation genetic testing is an automatic indication for ICSI.
ASRM’s 2026 guidance concludes that ICSI may be useful in selected patients undergoing PGT-M, which targets a specific monogenic condition, but does not recommend routine ICSI for PGT-A in the absence of male-factor infertility.
This distinction is particularly useful for patients because “PGT” is often discussed as though all genetic testing has identical laboratory requirements.
This is where recent evidence has become especially important.
ICSI is an impressive laboratory technique, but more intervention does not automatically produce a higher live-birth rate.
The 2026 ASRM committee opinion states that routine ICSI is not recommended in patients without male-factor infertility simply because they have:
The idea is understandable: perhaps an unknown fertilization problem explains the infertility, so directly injecting sperm could avoid it.
Some research has found fewer cases of total fertilization failure with ICSI.
But ASRM notes that improvement in fertilization has not translated into evidence of improved live birth, and therefore routine ICSI for unexplained infertility without male factor is not recommended.
The 2023 Cochrane review similarly found no clear superiority of ICSI over conventional IVF in couples with normal sperm count and motility for outcomes including live birth and clinical pregnancy.
A low ovarian reserve may mean fewer eggs are available.
It can feel intuitive to use the most technologically intensive fertilization method when every egg feels valuable.
However, current evidence does not demonstrate that routine ICSI improves live birth merely because ovarian reserve or oocyte yield is low when male-factor infertility is absent. ASRM’s 2026 guidance therefore does not recommend ICSI on this indication alone.
Advanced maternal age can reduce fertility, largely through factors related to oocyte quantity and chromosomal competence.
ICSI cannot reverse age-related changes within an egg.
ASRM’s 2026 review concludes that ICSI for advanced maternal age without male factor has not been shown to improve fertilization or live-birth outcomes.
ICSI helps sperm enter an egg.
It does not repair an immature or biologically compromised oocyte.
HFEA specifically states that when previous fertilization difficulty was caused by poor-quality or immature eggs, ICSI is unlikely to solve the problem.
This is an important treatment limit.
Neither is universally “better.”
The better fertilization method is the one that matches the diagnosed problem.
| Clinical situation | Conventional IVF | ICSI |
|---|---|---|
| Normal semen parameters, no previous fertilization failure | Often appropriate | Routine use not generally supported |
| Severe sperm abnormality | May have fertilization difficulty | Often considered |
| Very low usable sperm count | May be impractical | Often useful |
| Surgically retrieved sperm | Usually limited | Common indication |
| Previous total/very low IVF fertilization | Repeat failure possible | Frequently considered |
| Unexplained infertility with normal semen | Possible | Not routinely shown to improve live birth |
| Low AMH alone | Possible | Not automatically beneficial |
| Advanced maternal age alone | Possible | Not automatically beneficial |
| Poor egg quality | Limited by egg biology | Cannot correct egg quality |
| Frozen-thawed oocytes | Less commonly used | Recognized indication |
The table highlights a broader principle:
ICSI should be diagnosis-led, not technology-led.
ICSI can improve the likelihood of fertilization when the main barrier is sperm-related or when conventional insemination previously resulted in unexpectedly poor fertilization.
But fertilization rate is not the same as pregnancy rate.
This distinction matters enormously.
An IVF journey can be simplified into several stages:
egg retrieval → fertilization → embryo development → implantation → clinical pregnancy → live birth
ICSI directly intervenes primarily at the fertilization stage.
It does not ensure that:
HFEA therefore states that although ICSI is useful for fertilization, overall success depends on other factors including maternal age and female fertility factors, and separate ICSI pregnancy statistics are not necessarily meaningfully higher than IVF.
Not automatically.
In couples without a meaningful male-factor indication, evidence does not show that routine ICSI reliably increases live birth compared with conventional IVF.
A 2023 Cochrane analysis of randomized trials involving couples with normal sperm count and motility concluded that there was no evidence that either method was superior for live birth.
The 2026 ASRM opinion goes further, noting large contemporary studies in which non-indicated ICSI failed to improve reproductive outcomes and, in some observational datasets, was associated with lower reproductive efficiency.
That is why patients should ask:
“What problem in our case is ICSI intended to solve?”
rather than:
“Is ICSI more advanced than IVF?”
ICSI has an important but specific role.
Injecting sperm cannot reverse age-related or biological abnormalities inside the egg.
Some oocytes may fail to fertilize even after technically successful injection.
A fertilized egg still has to divide normally and continue developing.
ICSI is a fertilization technique, not genetic treatment.
Endometrial or uterine factors operate later in the reproductive process.
Pregnancy loss can arise from many causes that have nothing to do with the way sperm entered the egg.
Tubal, uterine, endocrine, ovarian, genetic and other fertility problems may require their own diagnostic and treatment strategy.
This is why comprehensive fertility assessment should precede selection of a laboratory technique.
Not necessarily.
Semen parameters can vary, and fertility assessment should consider the complete clinical picture.
NICE’s updated 2026 fertility guidance recommends confirming an abnormal semen-analysis result rather than making major fertility conclusions solely from one abnormal test, with timing adjusted when a severe abnormality such as azoospermia or severe oligozoospermia is present.
At Slavica IVF, semen analysis includes evaluation of count, motility and morphology.
The clinical question is not simply:
“Is one number below normal?”
It is:
“Do the semen findings create a meaningful risk that conventional fertilisation will fail?”
ICSI is widely used, but it is not risk-free.
HFEA notes that an egg can occasionally be damaged during preparation or injection. It also discusses a small observed association with some genetic or developmental conditions, while emphasizing that it is difficult to separate effects of the technique from effects related to the underlying infertility itself.
Another consideration arises when severe male infertility has a genetic cause.
A male child conceived using sperm from a man with certain heritable causes of infertility may inherit that genetic factor. HFEA therefore advises discussing genetic testing and counselling when relevant.
ICSI also adds:
ASRM specifically notes that routine non-indicated ICSI adds complexity and expense without proven live-birth benefit in many non-male-factor situations.
Before deciding, work through five questions.
Review:
Separate:
fertilization failure
from:
poor embryo development
from:
implantation failure.
ICSI primarily addresses the first.
Examples may include surgically retrieved sperm and fertilization of frozen-thawed oocytes.
That alone is not an evidence-based reason.
Ask whether the recommendation aims to improve:
These are not interchangeable endpoints.
If you have been told that you need ICSI because of an abnormal semen report or previous IVF result, the most useful next step is to review why fertilization may be at risk.
Slavica IVF offers fertility evaluation, semen analysis, IVF, ICSI treatment and surgical sperm-retrieval options in Sinamangal, Kathmandu.
When comparing an infertility clinic in Nepal or an IVF clinic in Kathmandu, do not choose solely on whether the clinic says it offers ICSI.
ICSI equipment alone does not decide the quality of care.
Ask:
A good fertility discussion should give you a rationale not simply a treatment acronym.
ICSI is a microsurgical laboratory procedure requiring embryology skill.
The embryologist must:
Slavica IVF lists Dr. Ajaya Jang Kunwar, PhD, as Chairman and Clinical Embryologist. His profile states training in clinical embryology and embryo biopsy and lists ICSI among his areas of expertise.
This reinforces an important patient question:
Who is actually performing and supervising the laboratory procedure?
A specialist review may be particularly appropriate when:
Slavica IVF’s fertility department includes Dr. Nikita Dhakal, MD Obstetrics & Gynaecology and IVF Specialist. Her profile lists fellowship training in IVF and reproductive endocrinology at the International Fertility Centre in New Delhi.
ICSI is most useful when there is a genuine fertilization barrier not simply because it is a more advanced laboratory technique.
Current guidance supports its use particularly with:
Routine ICSI is not currently recommended solely because of:
Remember the most important distinction:
ICSI can help sperm fertilize an egg. It cannot guarantee that the fertilized egg becomes a healthy embryo, implants, develops into a pregnancy or results in a live birth.
For couples considering IVF or ICSI in Nepal, the treatment decision should follow diagnosis, review of both partners and a clear explanation of why one fertilization method is being recommended over another.
Medical disclaimer: This article provides general fertility education. It cannot determine whether an individual couple should use IVF, ICSI, surgical sperm retrieval, genetic testing or another treatment. Fertility recommendations require review of medical history, semen testing, ovarian factors and previous treatment results.
ICSI is most commonly recommended when semen parameters are significantly abnormal, sperm must be surgically retrieved, or previous conventional IVF produced failed or very low fertilization. NICE’s 2026 fertility quality standard also includes frozen-thawed oocytes among recognized indications.
It may be. Very low sperm count is a well-recognized reason to consider ICSI because only a limited number of usable sperm may be available. The decision also depends on motility, morphology, laboratory preparation and previous fertility history rather than sperm concentration alone.
ICSI is not universally better than conventional IVF. It can be particularly helpful when there is a sperm-related fertilization problem, but routine ICSI has not been shown to improve live birth in many couples without male-factor infertility.
No. ASRM’s 2026 guidance does not recommend routine ICSI for every IVF cycle. Couples without male-factor infertility may often be suitable for conventional insemination unless there is another recognized indication.
It may be recommended when the previous IVF cycle specifically involved failed or unexpectedly low fertilization. If eggs fertilized normally but embryos later failed to develop or implant, ICSI may not address the underlying reason for failure.
Not routinely when semen parameters are normal. Some evidence suggests ICSI may reduce total fertilization failure, but current evidence has not demonstrated improved live birth, so ASRM does not recommend routine use solely for unexplained infertility.
Advanced maternal age alone is not considered sufficient reason for routine ICSI when there is no male-factor indication. ICSI cannot reverse age-related changes in egg quality.
Low AMH or diminished ovarian reserve alone does not mean ICSI will improve the chance of live birth. The decision should instead depend on semen factors, previous fertilization history and other specific indications.
No. ICSI helps a sperm enter a mature egg but does not improve the biological or chromosomal quality of the egg. HFEA notes that when poor or immature eggs are responsible for fertilization problems, ICSI is unlikely to solve the underlying issue.
No. Direct sperm injection can improve fertilization in appropriately selected cases, but not every injected mature egg will fertilize or continue developing normally.
No. ICSI influences primarily the fertilization step. Pregnancy also depends on egg competence, embryo development, chromosome status, endometrial factors, age and other clinical variables.
Yes, ICSI is commonly used when sperm are surgically retrieved from the epididymis or testicle because only limited numbers of sperm may be available. HFEA and NICE recognize surgically retrieved sperm as a clear indication.
